Bausch Health Companies Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Bausch Health Companies Inc. (BHC) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $5.82 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2014-02-28
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2013-09-30 was $0.00.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2013-06-30 was $3.96M.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2013-03-31 was $1.86M, a 9.71% decline year-over-year.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2013 was $5.82M, a 183.17% increase from fiscal 2012.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2012 was $2.06M, a 90.97% decline from fiscal 2011.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2011 was $22.78M.
- Bausch Health Companies Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2010 was -$11.60M.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $3.96M derived: sum of 3 quarters · filed 2014-02-28 | $5.82M 10-K · filed 2014-02-28 | |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 | $3.96M derived: sum of 2 quarters · filed 2013-11-01 | $5.82M 10-Q · filed 2013-11-01 | $5.85M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2013-06-30 | $3.96M 10-Q · filed 2013-08-07 | $5.82M 10-Q · filed 2013-08-07 | $5.85M derived: sum of 3 quarters · filed 2014-02-28 | $5.85M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2013-03-31 | $1.86M 10-Q · filed 2013-05-03 | $1.89M derived: sum of 2 quarters · filed 2014-02-28 | $1.89M derived: sum of 3 quarters · filed 2014-02-28 | $1.86M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2012-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $32.00K derived: sum of 2 quarters · filed 2014-02-28 | -$3.00K derived: sum of 3 quarters · filed 2014-02-28 | $2.06M 10-K · filed 2014-02-28 | |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-01 | -$35.00K derived: sum of 2 quarters · filed 2013-11-01 | $2.02M 10-Q · filed 2013-11-01 | $3.48M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2012-06-30 | -$35.00K 10-Q · filed 2013-08-07 | $2.02M 10-Q · filed 2013-08-07 | $3.48M derived: sum of 3 quarters · filed 2014-02-28 | $3.48M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2012-03-31 | $2.06M 10-Q · filed 2013-05-03 | $3.52M derived: sum of 2 quarters · filed 2014-02-28 | $3.52M derived: sum of 3 quarters · filed 2014-02-28 | $24.84M derived: sum of 4 quarters · filed 2014-02-28 | |
| 2011-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $1.46M derived: sum of 2 quarters · filed 2014-02-28 | $22.78M derived: sum of 3 quarters · filed 2014-02-28 | $22.78M 10-K · filed 2014-02-28 | $21.32M 10-K · filed 2013-02-28 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $21.32M derived: sum of 2 quarters · filed 2012-11-05 | $21.32M 10-Q · filed 2012-11-05 | ||
| 2011-06-30 | $21.32M 10-Q · filed 2012-08-03 | $21.32M 10-Q · filed 2012-08-03 | |||
| 2010-12-31 | -$11.60M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |